US2021069157A1PendingUtilityA1

Agent for treatment of pbc

Assignee: KOWA COPriority: Aug 25, 2016Filed: Feb 24, 2017Published: Mar 11, 2021

Est. expiryAug 25, 2036(~10 yrs left)· nominal 20-yr term from priority

Inventors:Mitsumasa Nakamura Satoshi Kojima Ryohei Tanigawa

A61K 31/421A61K 31/423A61P 1/16

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition for the treatment of primary biliary cirrhosis, containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , further containing a therapeutically effective amount of ursodeoxycholic acid. 
     
     
         3 . An agent for the reducing an alkaline phosphatase level, containing (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof as an active component. 
     
     
         4 . An agent for reducing a total bilirubin level, containing (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof as an active component.

Join the waitlist — get patent alerts

Track US2021069157A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.